Supercharging Immunotherapy · 2019-04-11 · Supercharging Immunotherapy April 2019 ©2019 HOOKIPA...
Transcript of Supercharging Immunotherapy · 2019-04-11 · Supercharging Immunotherapy April 2019 ©2019 HOOKIPA...
1©2019 HOOKIPA Pharma Inc.
Supercharging Immunotherapy
April 2019
2©2019 HOOKIPA Pharma Inc.
Disclaimer
This presentation contains forward-looking statements that can involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements
regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans
and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that may cause our actual results, level of activity, performance, events, circumstances or achievements to be materially different from any future results, level
of activity, performance, events, circumstances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “would” or “continue” or the negative of these terms or other similar
expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and
financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of
risks, uncertainties and assumptions.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-
looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those
projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all
risk factors and uncertainties.
3©2019 HOOKIPA Pharma Inc.
Why We Do, What We Do
Many diseases
exist or persist due to
“underperformance”
of the immune system
Immunotherapies must be sufficiently
potent to prevent or cure these
diseases
Sufficient potency of immunotherapies
must not compromise safety
Immunotherapies must be amenable
for broad use and not excessively
burden the health care system
Our TheraT® and VaxWave®
technologies are designed with a
goal to achieve all the above
1
2
3
4
4©2019 HOOKIPA Pharma Inc.
Our Reengineered Arenaviruses Are Designed To Reprogram The Immune System To Prevent Or Cure Infections And Cancer
Designed to effectively, safely,
and affordably combat infectious
diseases and cancer
Unique mode of action potentially leading to
cell therapy-like potency, with a well-tolerated
profile
Potent, durable T cell and antibody
responses; no meaningful vector-neutralizing
antibodies
Off-the-shelf, directly in-patient, systemic
and agnostic to route of administration
(intramuscular, intravenous, intratumoral)
Potential for easier and cost efficient
manufacturing
5©2019 HOOKIPA Pharma Inc.
We Are An Experienced, International Team With A Proven Track Record Of Building Biotech Companies
Joern Aldag
CEO & Director
uniQure, Evotec
Molecular Partners, G7, Unum
Daniel Pinschewer, MD
Founder and CSO
University of Basel, CH
Professor of Virology
Igor Matushansky, MD, PhD
CMO / Global Head of R&D
Daiichi Sankyo, Novartis Oncology
Columbia, Memorial Sloan Kettering
Reinhard Kandera, PhD
CFO & Director
Valneva, Intercell
Leadership
Michael A. Kelly (Former SVP at Amgen)
Paul-Henri Lambert, MD (Prof. Em. University of Geneva, Center of
Vaccinology)
Christoph Lengauer, PhD (Celsius Therapeutics, Blueprint Medicines,
Third Rock Ventures)
Julie O'Neill (Formerly, EVP Global Operations at Alexion Pharma)
Graziano Seghezzi (Sofinnova Partners)
Sander van Deventer, MD, PhD (uniQure, Forbion Capital Partners)
Jan van de Winkel, PhD
Chairman of the Board
Founder & CEO Genmab
Board of Directors
International Multidisciplinary Team 73 people
New York City, Vienna
6©2019 HOOKIPA Pharma Inc.
Our Platform, Strategy, And Finances –A Strong Basis To Deliver On Our Goals
Platform Strategy Investors
1 VaxWave® and TheraT® registered in Europe; pending in the US2 Refers to VaxWave® vector design; patents for TheraT ® vector design are pending
To improve the life of patients by
developing and commercializing
a new class of ‘‘off-the-shelf’’
immunotherapies to prevent
and treat infectious diseases
and cancer
• Phase 2 CMV program in solid
organ transplant recipients
• HIV, HBV therapeutics
(Gilead partnership $400m+)
• Cancer therapies based on viral
(HPV+), self (prostate), and
shared next-generation antigens
Two technologies using our proprietary arenavirus platform
VaxWave® 1
Replication-deficient
TheraT® 1
Replication-attenuated
Arenavirus family widely patented2
UNDISCLOSED U.S. PUBLIC LIFE
SCIENCES FUND
Sirona
Capital
7©2019 HOOKIPA Pharma Inc.
Building Blocks Of Our Strategy
Patient
Proof of Concept
Exploit Platform
• Expand target space to self-and shared next-generation antigens
• Expand immuno-oncology pipeline
• Build manufacturing in-house
• Deliver on Gilead partnership
Market Proprietary
Therapeutics
• VaxWave®: CMV Prophylaxis • Solid organ transplant patients • Phase 2 POC
• TheraT®: HPV+ cancers• Phase 1 safety and efficacy • Monotherapy• Combination therapy
Checkpoint Inhibitors Two different arenaviruses
administered sequentially
• Retain attractive commercial rights to products
• Build and scale-up regulatory and commercial presence in key markets
8©2019 HOOKIPA Pharma Inc.
Our Pipeline
Preclinical Phase 2Phase 1 Phase 3Antigen
gB/pp65
Undisclosed
Undisclosed
E6/E7
E6/E7
PSA/PSMA/
PAP
Target
CMV
HBV
HIV
HPV16+
Cancer
HPV16+
Cancer
Prostate
CancerImm
uno
-Oncolo
gy
Infe
ctious D
iseases Preliminary data
H1 2020
Anticipated
Milestones
IND H1 2019
Data late 2020/
early 2021
IND H1 2020
Data mid-2021
Compound
HB-101 (VaxWave®)
HBV
Therapy
HIV
Therapy
HB-201
(TheraT® LCMV)
HB-301 (TheraT®)
HB-202 (TheraT® PICV/
TheraT® LCMV)
Global
Rights
Development Stage
9©2019 HOOKIPA Pharma Inc.
Platform
10©2019 HOOKIPA Pharma Inc.
Arenaviruses: Harnessing Exceptional Viral Power To Drive Potent CD8+ T Cell Responses
The arenavirus LCMV was used by HOOKIPA co-founder
Prof. Rolf Zinkernagel for his Nobel Prize-winning research and
discoveries regarding the role of the MHC-complex in T cell immunity
HOOKIPA co-founder Daniel Pinschewer reengineered the arenavirus
LCMV to redirect the exceptionally potent T cell response of this virus
against cancer and infectious disease-specific antigens
VaxWave®
Replication-deficient
TheraT®
Replication-attenuated
Arenavirus genomes are reengineered as vectors HOOKIPA Patent Estate
covering all arenaviruses1
Pichinde Virus (PICV)
Lymphocytic Choriomeningitis
Virus (LCMV)
Flatz et al. Nature Medicine 2010
1 Refers to replication-deficient arenaviruses; patents for replication-attenuated arenaviruses are pending
Arenavirus Family
11©2019 HOOKIPA Pharma Inc.
Arenavirus Technologies Can Be “Titrated” To Trigger >50% Antigen-Specific CD8+ T Cells
TheraT® superior potency compared to other technologies
Note: Comparison in mice of TheraT® (LCMV) and TheraT® (LCMV - PICV) heterologous prime-boost vs modified vaccinia virus Ankara (MVA), and recombinant Adenovirus 5-based (rAd5) vectors,
each expressing the E7 antigen, for their ability to induce E7-specific CD8+ T cells
0
2
4
6
1 0
2 0
3 0
4 0
5 0
6 0E
7-T
et+
CD
8
T c
ell
s
(%)
M o d if ie d v a c c in ia v ir u s
A n k a r a
(M V A ) 1 09
A d e n o v iru s ( rA d 5 ) 1 09
H O O K IP A a re n a v iru s
S in g le v ir u s L C M V 1 07
H O O K IP A a re n a v iru s
c o m b o L C M V + P IC V
v e c to r s 1 05
Arenavirus vectors Other viral vectors
HPV+ cancer
antigen (E7) -
specific CD8 T cells
109
109107
105
12©2019 HOOKIPA Pharma Inc.
TheraT® triggers alarmin (interleukin-33)
release, potentiating CD8+ T cell
proliferation
TheraT® Supercharges The Immune System: Superior CD8+ T Cell Quantity And Quality
TheraT® induces Tox1 in CD8+ T cells,
rendering them checkpoint insensitive
1 Kallert, S. et al. Nature Communications 2017;
2 Page, N. et al. Immunity 2018
1 2
13©2019 HOOKIPA Pharma Inc.
Arenavirus-based Therapies Are Simple “Off-the-shelf” For Direct In-patient Use
14©2019 HOOKIPA Pharma Inc.
Key Differentiating Features of HOOKIPA’s Arenavirus Platform
Arenaviruses: work horse of immunologists for decades
• Naturally target and activate dendritic cells (DCs) No complex ex-vivo logistics required
Entirely self-adjuvanted
• Reprogram the body’s immune system Robust, durable CD8 T cell responses
Potent, durable antibody responses against pathogens
• “Glycan shield”: No meaningful vector-neutralizing antibodies Allows for efficient repeat administration
• Proven to be well-tolerated in humans Phase 1 CMV trial: very limited adverse events, notably no cytokine release syndrome
Use of wildtype LCMV in patients to led to flu-like symptoms only1
Flatz et al. Nature Medicine 2010
1 Webb et al Clinical Oncology 1975
15©2019 HOOKIPA Pharma Inc.
Infectious Diseases
16©2019 HOOKIPA Pharma Inc.
HB-101 To Address Significant Unmet Medical Need In Cytomegalovirus (CMV) Infections
• Liquid formulations of
VaxWave® gB vector
(B cell antigen)
VaxWave® pp65 vector
(T cell antigen)
• Activates both arms of adaptive immune system
Induces neutralizing antibodies to gB
Induces T cells against pp65
• Intra-muscular administration
• Prevalence, incidence
Approximately 60% of US population1, up
to 99% in less industrialized regions
latently infected
110k patients added p.a. to organ
transplant list in key relevant countries2
• No licensed prophylactic CMV vaccine exists
• CMV risks and symptoms in transplant
patients
Infection and/or re-activation
Fever, pneumonitis, colitis, hepatitis,
retinitis, ultimately transplant rejection or
death
• CMV congenital infection is a significant
further unmet medical need
CMV Unmet Medical Need Our Solution: HB-101
1 CDC Cytomegalovirus (CMV) and Congenital CMV Infectionhttps://www.cdc.gov/cmv/index.html; 2 US, EU, Canada, Australia, Japan
17©2019 HOOKIPA Pharma Inc.
A n tib o d y Im m u n o g e n ic ity
(H C M V g B1 E L IS A )
0 2 0 4 0 6 0
1 0
1 0 0
1 0 0 0
P la c e b o
L o w D o s e
M e d iu m D o s e
H ig h D o s e
T im e (w e e k s )
GM
T A
EU
/ml
+-
95
%C
I2Trial design: 54 healthy, CMV-negative adults; 3 administrations (month 0, 1, 3; as shown by on x-axis below);
3 doses (2.6x106, 2.6x107, 2.6x108 FFU), placebo-controlled
Results: Robust CD8+ and CD4+ Tcell andCMV-neutralizing antibody responses;nomeaningfulvector-neutralizing antibodies, well-tolerated
HB-101 – Phase 1 Trial Completed: Well-Tolerated, Potent and Durable Antibody & T Cell Responses
H ig h D o s eL o w D o s e
d0
0
d2
8
d8
4
m0
4
m1
2
d0
0
d2
8
d8
4
m0
4
m1
2
d0
0
d2
8
d8
4
m0
4
m1
2
d0
0
d2
8
d8
4
m0
4
m1
2
30
_S
N
1_
SP
1 0
1 0 0
N o N e u tra liz in g A n tib o d ie s
(L C M V N T A )
c u t-o ff
M e d iu m D o s e C trlP la c e b o
LC
MV
Ne
utr
ali
za
tio
n T
ite
r
1 B cell antigen; 2 GMT= geometric mean titer, AEU= arbitrary ELISA units, CI= confidence interval;
18©2019 HOOKIPA Pharma Inc.
Dose dependent, durable CMV phosphoprotein 65 (pp65) specific CD8+ T cells following 3 injections of HB-101
HB-101 – Strong Antigen-specific T Cell Immunogenicity Demonstrated In Phase 1 Clinical Trial
H B -1 0 1 P h a s e 1 T c e ll im m u n o g e n ic ity
0 4 0 8 0 1 2 0 1 6 0 2 0 0 2 4 0 2 8 0 3 2 0 3 6 0
0 .0
0 .1
0 .2
0 .3
0 .4P la c e b o
M e d iu m D o s e
H ig h D o s e
L o w D o s e
D a y s a fte r firs t v a c c in a tio n
CM
V p
p6
5 s
pe
c.
INF
g+
CD
8 T
ce
lls
(%
)
19©2019 HOOKIPA Pharma Inc.
Third Party Adoptive Cell Therapy Trial Demonstrated pp65-Specific T Cell Levels Which Were Therapeutic/Curative
CMV viral load
Total CMV pp65 specific CD8 T cells (%)
CMV pp65 specific IFNg+ CD8 T cells (%)
Neuenhahn et al., Leukemia 2017
Phosphoprotein 65 (pp65) - specific CD8+ T cells isolated from CMV+ donoradministered to patients with active CMV viremia were curative1
1 The results presented on this slide have been derived from publicly available reports of clinical trials run independently by third parties. We have not performed any head-to-head trials
comparing any of these other therapeutic approaches with HB-101. As such, the results of these other clinical trials may not be comparable to clinical results for HB-101. The design of
these other trials vary in material ways from the design of the clinical trials for HB-101.
20©2019 HOOKIPA Pharma Inc.
HB-101 – Phase 2 CMV Trial Ongoing In Solid Organ Transplantation
HB-101 CMV Ph2 Solid Organ Transplant Patients
Patient Population
Patients
Endpoints
Expected Read-out
Live donor kidney transplant patients, high risk of CMV viremia, (i.e. CMV negative recipients and CMV positive donors)
• 150, randomized 2:1 study drug vs placebo
• Treated pre-transplant
• Stratified by post-transplant treatment intent Pre-emptive antiviral therapy (50 patients)
6 months prophylactic antiviral therapy (100 patients)
• Primary: immunogenicity and safety
• Secondary: reduction of viremia rate (Goal > 50%),
decreased use of antivirals
• H1 2020: Primary endpoint safety/reactogenicity
• H2 2020: Preliminary 3M efficacy post transplant (pre-emptive)
• 2021: Final 12M efficacy post transplant (pre-emptive & prophylactic)
21©2019 HOOKIPA Pharma Inc.
Immuno Oncology
22©2019 HOOKIPA Pharma Inc.
• TheraT® targets lymph nodes, dendritic cells; activates T cells in an antigen-specific manner
• Sets off IL-33 pathway, which leads to increased proliferation of T cells
• Leads to greater tumor infiltration
TheraT® Turning “Cold” Tumors “Hot”- Tumor Infiltration by Cytotoxic T Cells Stronger Than Adenovirus1
TheraT ® -TAA2
Tumor
CD8 T cells migrate from lymph nodes to tumor
Antigen-specific CD8 T cell activation
Lymph Nodes/ Dendritic Cells
1 Recombinant Adenovirus; 2 Tumor Associated Antigen
Source: Kallert, S. et al. Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumor immunotherapy; NATURE COMMUNICATIONS | 8:15327 | DOI:10.1038/ncomms15327, 9 (2017)
Untreated Adenovirus Arenavirus
Delivery
Antigen -
-
OVA
Adeno Arenavirus
GFP (irrelevant)
Arenavirus
OVA
23©2019 HOOKIPA Pharma Inc.
0 1 2 4 6 82 0 2 2 2 4 2 6 2 8 3 0 3 9 4 3 4 5 4 7 5 3 6 0
0
5 0 0
1 0 0 0
1 5 0 0
D a y s a fte r s e c o n d a ry c h a lle n g e
Tu
mo
r v
olu
me
(m
m3
)
* *
0 5 0 1 0 0 1 5 0 2 0 0
0
2 0
4 0
6 0
8 0
1 0 0
D a y s
Pe
rce
nt
su
rviv
al
(%)
In tra v e n o u s
In tra tu m o ra l
B u ffe r c o n tro l IT
* * * *P < 0 .0 0 0 1
Single Applications Of TheraT® Show Potent Effect In Controlling Tumors And Prevents Recurrence (HPV+ Cancer (TC1))
HPV+ Cancer Challenge: TheraT ® Treatment Re-challenge
Strong tumor control in a metastatic setting
• 40% of mice cured1 for up to 150 days
Approach appropriate for treatment of
• Metastatic disease
• Primary disease and subsequent prevention of
metastatic recurrence
PICV
0 5 0 1 0 0 1 5 0
0
2 0
4 0
6 0
8 0
1 0 0
D a y s
Pe
rce
nt
su
rviv
al
(%)
* * * *P < 0 .0 0 0 1
In tra v e n o u s
In tra tu m o ra l ( IT )
B u ffe r IT
Previously cured1 by treatment with
TheraT® (LCMV) intratumoral
Previously cured1 by treatment with
TheraT® (PICV) intravenous
Challenged with tumor
for the first time
1 Defined as complete remission without recurrence for at least six months
LCMV
D140: Re-
challenged with
tumor cells
D180: Re-
challenged with
tumor cells
24©2019 HOOKIPA Pharma Inc.
• Direct correlation
between dose and
immunogenicity
• Direct correlation
between dose and
efficacy
• Direct correlation
between
immunogenicity and
efficacy
HB-201 HPV+ Cancer Pre-IND Package: Dose Dependent Tumor Control, Correlating With Immunogenicity
HB-201 Dose
HP
V+
specific
T c
ells
(%
of to
tal)
low medium highbuffer
5
4
3
2
1
0
0 5 1 0 1 5 2 0 2 5
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
D a y s p o s t tre a tm e n t
Tu
mo
r V
olu
me
[m
m3
]
B u ffe r
M e d iu m D o s e
H ig h D o s e
L o w D o s e1 5 0 0
2 0 0 0
Immunogenicity-Dose Tumor Control-Dose (Efficacy)
25©2019 HOOKIPA Pharma Inc.
HB-201 – Clinical Study Design (Study H-200-001) To Validate Intravenous And Intratumoral Applications In HPV+ Tumors
Phase 2 Dose EXPANSIONPhase 1 Dose ESCALATION
Other HPV+ cancers
(cervical, anal, penile, etc.)1
Intratumoral
HPV+ HNSCC for metastatic tumor
3rd line
Intravenous
HPV+ HNSCC combination with nivolumab
2nd line
Intravenous
Other HPV+ cancers1
Intratumoral
H1 2019:
IND filing with FDA
H2 2019:
Initiate Phase 1/2
clinical trial
late 2020/ early 2021:
Preliminary results
expected
HPV+ Head & Neck Squamous Cell
Carcinoma (HNSCC)
Intravenous
Arm 1:
(n=20)
Arm 2:
(n=20)
Arm 3:
(n=20)
Group 1:
(n=20)
Group 2:
(n=20)
1 First dose HB-201 into cancer accessible for intratumoral injection, subsequent doses intravenous
26©2019 HOOKIPA Pharma Inc.
0 2 0 4 0 6 0 8 0 1 0 0 1 2 0
0
5 0
1 0 0
1 4 0 1 6 0 1 8 0
T im e a fte r tu m o r c e ll e n g ra ftm e n t (d a y s )
Pe
rce
nt
su
rviv
al
(%)
T he raT®
(P IC V )-T h e ra T®
(L C M V )
B u ffe r
T he raT®
(P IC V )-T h e ra T®
(P IC V )
T he raT®
(L C M V )-T h e ra T®
(L C M V )
1
Under More Aggressive Conditions - Only Sequential Administration Of TheraT® (PICV) & TheraT® (LCMV) Increased Anti-Tumor Activity And Survival
TC-1 model (HPV+ cancer)
D120: Re-
challenged with
tumor cells
• Sequential
administration of
TheraT® (PICV) and
TheraT® (LCMV) is
more potent than either
one alone
• Re-challenging long
term survivors with
more tumor results in
no additional tumor
growth
In pre-clinical trials, a sequential administration of two arenaviruses is superior to repeated administration of either one alone in elimination of large tumor and protection from subsequent tumor re-challenge
1 One additional animal euthanized due to open tumor.
27©2019 HOOKIPA Pharma Inc.
Phase 2 Dose EXPANSION
HB-202 & HB-201 Sequential Administration Study Design (Trial H-200-002) To Prove Optimum Tumor Control
1st dose HB-201 given as intratumoral
injection; subsequent dose HB-202, then
HB-201 and HB-202 both intravenous in
sequential alternating manner
HB-202 and HB-201 sequential alternating
intravenous application;
HB-202 administered first, HB-201 several
weeks later
Arm 1:
(n=20)
Arm 2:
(n=20)
Arm 3:
(n=20)
Group 1:
(n=20)
Group 2:
(n=20)
HPV 16+ metastatic tumor
3rd Line
Intravenous
HPV 16+ tumors
2nd Line in combination with nivolumab/PD-1
Intravenous
HPV 16+ cancers accessible for intratumoral injection;
Intratumoral and intravenous
Phase 1 Dose ESCALATION
H1 2020:
IND filing with FDA
H2 2020:
Initiate Phase 1/2 trial
2021:
Preliminary results
expected (Group 1+2,
1st 3 cohorts efficacy = POC
28©2019 HOOKIPA Pharma Inc.
• Single systemic TheraT® injection can lead to complete remission without recurrence for at least 6 months,
eliminating both primary tumor and lung metastasis
• Agnostic to the injection site (sub-cutaneous, intravenous, or intratumoral)
• Potential to turn tumors hot by intravenous or intratumoral injections
• Antigen specific “abscopal-like” mechanism
Efficacy in Melanoma Model Demonstrates Potential In Metastatic Disease by Targeting Melanoma Self-Antigen
DAY
17:
Day 1:
Tumor cells
Day 4:
Tumor cells
Day 7:
TheraT® (LCMV)1
In collaboration
with Lukas Flatz,
Kantonspital St. Gallen
TheraT® treatedUntreated
1 Intratumoral treatment leads to a 40% cure rate on main tumor (complete remission until end of observation period (100 days))
Day 1:
Tumor cells
Day 4:
Tumor cells
29©2019 HOOKIPA Pharma Inc.
Key Financials, Investment Highlights
29©2019 HOOKIPA Pharma Inc.
Key Financials, Investment Highlights
30©2019 HOOKIPA Pharma Inc.
HOOKIPA Manufacturing – High Degree Of Validation And Clear Production Network Strategy
Clinical Manufacturing
OrganizationsDedicated CMO Production
Suite
Production Network
Strategy
Manufacturing collaboration
to access dedicated
manufacturing suite
• Partner Valneva Sweden
• Analytical services, develop
process scale-up, produce GMP
clinical trial material of VaxWave® &
TheraT® vectors
• Ring-fenced space and
human resources
VaxWave®
• Process developed & transferred
to Sigma Aldrich
• Phase 1/2 CMV material
manufactured successfully
TheraT®
• Process developed & transferred
to ABL and IDT
• Tox lots, engineering runs
successfully completed
HOOKIPA-controlled
manufacturing facility &
outsourcing
• Strategic review underway with a
goal to determine the mix of
proprietary and out-sourced
manufacturing
31©2019 HOOKIPA Pharma Inc.
Financing History
• $142.5m raised to date
Series D $37.4m (Feb. 2019)
Series C $59.4m
Series B $36.1m
Series A $9.5m
• $8.3m R&D loans from
government agencies
• December 31, 2018 pro forma cash
balance: $85.9m(pro forma adjusted for Series D net
proceeds)
Executing on Financial Strategy To Support Pipeline Progression
Key Financial Data
in $ million
Year ended
December 31,
2017
Year ended
December 31,
2018
Revenue from collaboration & licensing – 7.6
R&D expenses (9.8) (22.0)
G&A expenses (4.4) (6.8)
Net loss (12.7) (16.2)
in $ million
As of Dec. 31,
2017
As Dec. 31,
2018
Cash and cash equivalents 61.4 48.6
Total assets 73.7 68.3
Total liabilities 11.6 23.9
Equity and convertible preferred stock 62.1 44.4
32©2019 HOOKIPA Pharma Inc.
Investment Highlights
Unique arenavirus MoA
potentially leads to cell therapy-like potency,
well-tolerated safety profile
Strong leadership, board and investor
syndicate
Universal off-the shelf approach for
B- and T-cell immunity targeting large markets
Phase 2 POC CMV trial ongoing
Arenavirus technology capable of
reprogramming the immune system to
potentially prevent or cure many infectious
diseases and cancers
33©2019 HOOKIPA Pharma Inc.
Supercharging Immunotherapy